GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Medtronic, Inc. (MDT) [hlAlert]

Rating:
Mkt Perform
MDT
down 36.87 %

Medtronic, Inc. (MDT) downgraded to Mkt Perform by Leerink Swann

Posted on: Tuesday,  Jan 6, 2009  8:25 AM ET by Leerink Swann

Leerink Swann rated Mkt Perform Medtronic, Inc. (NYSE: MDT) on 01/06/2009. Previously Leerink Swann rated Outperform Medtronic, Inc. (NYSE: MDT)
on 06/03/2008., when the stock price was $50.61. Since then, Medtronic, Inc. has lost 36.87% as of 01/06/2009's recent price of $31.95.
If you would have followed the previous Leerink Swann 's recommendation on MDT, you would have lost 36.87% of your investment in 217 days.

Medtronic, Inc. (Medtronic) is a global player in medical technology. The Company operates in seven segments that manufacture and sell device-based medical therapies: Cardiac Rhythm Disease Management, Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies and Physio-Control. Through these seven segments, the Company develops, manufactures and markets its medical devices in more than 120 countries. Its primary products include those for cardiac rhythm disorders, cardiovascular disease, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, diabetes, and ear, nose and throat conditions. The primary markets for products are the United States, Western Europe and Japan. In July 2008, it acquired Restore Medical, Inc. In November 2008, Medtronic acquired CryoCath Technologies Inc. In February 2009, it acquired Ablation Frontiers, Inc. and Ventor Technologies Ltd. In April 2009, Medtronic acquired CoreValve, Inc.

Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions. Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/6/2009 8:25 AM Hold
None
31.95
as of 12/31/2009
1 Week   
1 Month   
3 Months   
1 YTD up  1.68 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/3/2008 8:25 AM Buy
None
50.61

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy